Zanrong Pharmaceutical Technology

Zion Pharma (Zanrong Pharmaceutical Technology) is a clinical-stage biopharmaceutical company founded in 2018, specializing in the discovery and development of innovative small-molecule oncology therapeutics. The company leverages a proprietary platform focused on Drug Metabolism and Pharmacokinetics (DMPK) to design "best-in-class" and "first-in-class" drugs, with a specific emphasis on achieving high blood-brain barrier (BBB) penetration. Its lead candidate, perzebertinib (ZN-A-1041), is a BBB-penetrant HER2 tyrosine kinase inhibitor currently in Phase 1/2 trials for HER2-positive breast cancer and brain metastases. In 2023, Zion Pharma entered into a significant global licensing agreement with Roche for perzebertinib, valued at up to $680 million. The company is headquartered in Hong Kong with research and development facilities in Suzhou and Shanghai, China. Zion Pharma continues to advance a pipeline of internal programs targeting ATM, KRAS, and SMARCA2.